Why the study?
The incidence of adverse events remains high after a first episode of stent thrombosis.
Do new-generation P2Y12 inhibitors, additional stenting, GP IIb/IIIa inhibitors, or thrombectomy improve outcomes in patients after a first definite coronary stent thrombosis?
Do new-generation P2Y12 inhibitors, additional stenting, GP IIb/IIIa inhibitors, or thrombectomy improve outcomes in patients after a first definite coronary stent thrombosis?
Answers are grounded in this paper and cite their sources.
Following a first coronary stent thrombosis, new-generation P2Y12 inhibitors reduce the risk of subsequent MI, while additional stenting, GP IIb/IIIa inhibitors, and thrombectomy do not appear to improve outcomes.
The incidence of adverse events remains high after a first episode of ST. New-generation P2Y12 inhibitors reduce the risk of MI. Additional stenting, GP IIb/IIIa inhibitors and thrombectomy did not improve outcomes following ST.
No takes yet. Share an insight, caveat, or question.
Forero et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: